Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3′,5′ monophosphate accumulation and adenosine 3′5′ triphosphate release from human erythrocytes

Experimental Biology and Medicine

Volumn 238, Issue 9, 2013, Pages 1069-1074

  Knebel, Stephanie M ^a   Elrick, Mollisa M ^a   Bowles, Elizabeth A ^a   Zdanovec, Amber K ^a   Stephenson, Alan H ^a   Ellsworth, Mary L ^a   Sprague, Randy S ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

iloprost; Phosphodiesterase 5; tadalafil; UT 15C; zaprinast

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CILOSTAZOL; HEMOGLOBIN; ILOPROST; N, N DIMETHYLFORMAMIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; TADALAFIL; TREPROSTINIL; UNCLASSIFIED DRUG; ZAPRINAST;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; MALE; OXYGEN TENSION; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION;

ILOPROST; PHOSPHODIESTERASE 5; TADALAFIL; UT-15C; ZAPRINAST;

ADENOSINE TRIPHOSPHATE; ADULT; CARBOLINES; CYCLIC AMP; EPOPROSTENOL; ERYTHROCYTES; FEMALE; HUMANS; ILOPROST; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PURINONES; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 84884265442     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213498981     Document Type: Article

References (39)

1. Agarwal R,Gomberg-Maitland M.Current therapeutics and practical management strategies for pulmonary arterial hypertension.Am Heart J. 2011;162:201-13.
2. Anderson JR,Nawarskas JJ.Pharmacotherapeutic management of pulmonary arterial hypertension.Cardiol Rev. 2010;18:148-62.
3. Rich S,Dantzker DR,Ayres SM,Bergofsky EH,Brundage BH,Detre KM,Fishman AP,Goldring RM,Groves BM,Koerner SK,Levy PC,Reid LM,Vreim CE,Williams GW.Primary pulmonary hypertension. A national prospective study.Ann Intern Med. 1987;107:216-23.
4. Peacock AJ,Murphy NF,McMurray JJ,Caballero L,Stewart S.An epidemiological study of pulmonary arterial hypertension.Eur Respir J. 2007;30:104-9.
5. Wise H.Multiple signalling options for prostacyclin.Acta Pharmacol Sin. 2003;24:625-30.
6. Clapp LH,Finney P,Turcato S,Tran S,Rubin LJ,Tinker A.Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery.Am J Respir Cell Mol Biol. 2002;26:194-201.
7. Woodward DF,Jones RL,Narumiya S.International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress.Pharmacol Rev. 2011;63:471-538.
8. Sprague RS,Goldman D,Bowles EA,Achilleus D,Stephenson AH,Ellis CG,Ellsworth ML.Divergent effects of low-O2 tension and iloprost on ATP release from erythrocytes of humans with type 2 diabetes: implications for O2 supply to skeletal muscle.Am J Physiol Heart Circ Physiol. 2010;299:H566-73.
9. Sprague RS,Bowles EA,Hanson MS,DuFaux EA,Sridharan M,Adderley S,Ellsworth ML,Stephenson AH.Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes.Microcirculation. 2008;15:461-71.
10. Dietrich HH,Ellsworth ML,Sprague RS,Dacey RG.Red blood cell regulation of microvascular tone through adenosine triphosphate.Am J Physiol Heart Circ Physiol. 2000;278:H1294-8.
11. Sprague RS,Bowles EA,Olearczyk JJ,Stephenson AH,Lonigro AJ.The role of G protein beta subunits in the release of ATP from human erythrocytes.J Physiol Pharmacol. 2002;53 (4, Pt 1): 667-74.
12. Sprague RS,Ellsworth ML,Stephenson AH,Lonigro AJ.Increases in perfusate flow rate stimulate ATP release from red blood cells in isolated rabbit lungs.Exp Clin Cardiol. 1998;3:73-7.
13. Sprague RS,Ellsworth ML,Stephenson AH,Lonigro AJ.ATP: the red blood cell link to NO and local control of the pulmonary circulation.Am J Physiol. 1996;271 (6, Pt 2): H2717-22.
14. Sprague RS,Olearczyk JJ,Spence DM,Stephenson AH,Sprung RW,Lonigro AJ.Extracellular ATP signaling in the rabbit lung: erythrocytes as determinants of vascular resistance.Am J Physiol Heart Circ Physiol. 2003;285:H693-700.
15. Ellsworth ML.The red blood cell as an oxygen sensor: what is the evidence?.Acta Physiol Scand. 2000;168:551-9.
16. Sprague RS,Stephenson AH,Ellsworth ML.Red not dead: signaling in and from erythrocytes.Trends Endocrinol Metab. 2007;18:350-5.
17. Baillie GS.Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases.FEBS J. 2009;276:1790-9.
18. Hayes JS,Brunton LL.Functional compartments in cyclic nucleotide action.J Cyclic Nucleotide Res. 1982;8:1-16.
19. Matsumoto T,Kobayashi T,Kamata K.Phosphodiesterases in the vascular system.J Smooth Muscle Res. 2003;39:67-86.
20. Zaccolo M.Phosphodiesterases and compartmentalized cAMP signalling in the heart.Eur J Cell Biol. 2006;85:693-7.
21. Adderley SP,DuFaux EA,Sridharan M,Bowles EA,Hanson MS,Stephenson AH,Ellsworth ML,Sprague RS.Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans.Am J Physiol Heart Circ Physiol. 2009;296:H1617-24.
22. Hanson MS,Stephenson AH,Bowles EA,Sridharan M,Adderley S,Sprague RS.Phosphodiesterase 3 is present in rabbit and human erythrocytes and its inhibition potentiates iloprost-induced increases in cAMP.Am J Physiol Heart Circ Physiol. 2008;295:H786-93.
23. Adderley SP,Thuet KM,Sridharan M,Bowles EA,Stephenson AH,Ellsworth ML,Sprague RS.Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5.Med Sci Monit. 2011;17:CR241-7.
24. Murthy KS,Zhou H,Makhlouf GM.PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.Am J Physiol Cell Physiol. 2002;282:C508-17.
25. Harrison SA,Reifsnyder DH,Gallis B,Cadd GG,Beavo JA.Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.Mol Pharmacol. 1986;29:506-14.
26. Strehler B,McElroy WMethods in Ezymology. Colowick SKaplan N, ed. New York: Academic Press; 1957:871-3.
27. Adderley SP,Sridharan M,Bowles EA,Stephenson AH,Ellsworth ML,Sprague RS.Protein kinases A and C regulate receptor-mediated increases in cAMP in rabbit erythrocytes.Am J Physiol Heart Circ Physiol. 2010;298:H587-93.
28. Chalmers C,Bird BD,Whitwam JG.Evaluation of a new thin film tonometer.Br J Anaesth. 1974;46:253-9.
29. Sprague RS,Hanson MS,Achilleus D,Bowles EA,Stephenson AH,Sridharan M,Adderley SP,Procknow JD,Ellsworth ML.Rabbit erythrocytes release ATP and dilate skeletal muscle arterioles in the presence of reduced oxygen tension.Pharmacol Rep. 2009;61:183-90.
30. Holownia P,Bishop E,Newman DJ,John WG,Price CP.Adaptation of latex-enhanced assay for percent glycohemoglobin to a Dade Dimension analyzer.Clin Chem. 1997;43:76-84.
31. Conran N,Oresco-Santos C,Acosta HC,Fattori A,Saad ST,Costa FF.Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients.Br J Haematol. 2004;124:547-54.
32. Sung BJ,Hwang KY,Jeon YH,Lee JI,Heo YS,Kim JH,Moon J,Yoon JM,Hyun YL,Kim E,Eum SJ,Park SY,Lee JO,Lee TG,Ro S,Cho JM.Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.Nature. 2003;425:98-102.
33. Olearczyk JJ,Stephenson AH,Lonigro AJ,Sprague RS.Receptor-mediated activation of the heterotrimeric G-protein Gs results in ATP release from erythrocytes.Med Sci Monit. 2001;7:669-74.
34. Olearczyk JJ,Stephenson AH,Lonigro AJ,Sprague RS.Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release from erythrocytes.Am J Physiol Heart Circ Physiol. 2004;286:H940-5.
35. Keen M,Kelly E,MacDermot J.Prostaglandin receptors in the cardiovascular system: potential selectivity from receptor subtypes or modified responsiveness.Eicosanoids. 1989;2:193-7.
36. Fares WH,Trow TK.Targeted approaches to the treatment of pulmonary hypertension.Ther Adv Respir Dis. 2012;6:147-59.
37. Safdar Z.Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.Respir Med. 2011;105:818-27.
38. Pickles H,O'Grady J.Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.Br J Clin Pharmacol. 1982;14:177-85.
39. Heavey DJ,Lumley P,Barrow SE,Murphy MB,Humphrey PP,Dollery CT.Effects of intravenous infusions of prostaglandin D2 in man.Prostaglandins. 1984;28:755-67.